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Heterodimerization of G protein-coupled receptors has become increasingly recognized as a valuable mech-
anism to increase receptor diversity. Heterodimers have been observed in the opioid receptor family, but one
of the most intriguing is that formed between m-opioid and d-opioid receptors. In this issue of Neuron, He
et al. present evidence further implicating these heterodimers in morphine tolerance.Understanding opioid tolerance has long
been a goal in the opioid field. Recent
years have revealed many new and ex-
citing observations regarding the under-
lying the processes. These involve many
different and unrelated mechanisms,
making the integration of these pathways
very difficult. Opioid tolerance is the
diminished response seen with chronic
administration of a drug or, put another
way, the need to progressively increase
drug doses to maintain a response. Toler-
ance is the final common pathway for
a wide range of divergent mechanisms,
much like a tug of war with many different
people pulling on the same rope. Each is
contributing to the final effort and the
loss of any one of them can have a similar
effect. In this issue of Neuron, He et al.
(2011) describe results that support the
concept that one aspect of tolerance is
mediated through m/d heterodimers and
present a mechanism explaining the
ability of d-opioid receptor (DOR) antago-
nists to prevent tolerance to morphine.
Morphine tolerance involves many
distinct systems and can be influenced in
many ways. The first was put forward by
Collier (1980), who proposed what he
referred to as a ‘‘hypertrophy of the cyclicAMP system.’’ This was followed by the
identification of the role of other neuro-
transmitter systems, as illustrated by
the loss of morphine tolerance with
blockade of the N-methyl-D-aspartate
(NMDA) receptor/nitric oxide cascade.
Many classes of NMDA receptor antago-
nists can effectively prevent or reverse
morphine tolerance (Trujillo and Akil,
1991), as can inhibition of nitric oxide
synthase (Kolesnikov et al., 1997). The
importance of dispositional issues was
established by studies on P-glycoprotein
(King et al., 2001). Chronic administration
of morphine upregulates P-glycoprotein,
which in turn decreases morphine
penetration into the brain. Knocking out
Pgp prevents morphine tolerance. Most
recently, investigators have explored
receptor trafficking (Von Zastrow, 2010)
and suggested a role for m-opioid/d-opioid
receptor (MOR/DOR)heterodimers (Gupta
et al., 2010). These various differentmech-
anisms are not exclusive and all probably
contribute to the overall response.
The role of d systems in morphine toler-
ance was first proposed by Takemori and
coworkers (Abdelhamid et al., 1991), who
showed that the DOR antagonist naltrin-
dole prevents morphine tolerance. Theimportance of DORs was confirmed by
studies in DOR knockout mice and anti-
sense downregulation models that also
revealed the loss of morphine tolerance.
In the current paper by He and coworkers
(He et al., 2011), the authors find that
spinal delivery of the d ligand deltorphin I
diminished morphine actions, consistent
with an inhibitory modulation of morphine
analgesia. The opioid field has long had
controversies and data that appear
contradictory, and the role of d systems
in morphine action is no exception. Soon
after their discovery, enkephalins, endog-
enous DOR ligands, were shown to be
potent analgesics given either spinally or
supraspinally. Furthermore, Porreca and
coworkers (Porreca et al., 1987) demon-
strated that d ligands given supraspinally,
but not spinally, potentiated morphine
analgesia in naive and tolerant mice.
Thus, d drugs can both potentiate and
diminish morphine analgesia. A number
of potential explanations for these con-
flicting results are possible, including
the site of action (i.e., spinal versus
supraspinal), since potentiation was pre-
viously seen only supraspinally while the
decreased effect in the current paper
was documented at the spinal level.
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Figure 1. Schematic on the Interaction of the
Engineered MORTM1-TAT with MOR /DOR
Heterodimers
In this schematic, morphine (MOR-1; red) and d (DOR-1;
orange) form heterodimers. Addition of the engineered
MORTM1-TAT, which includes the sequence of the first
transmembrane domain of MOR-1, leads to the disruption
of the heterodimer.
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PreviewsHowever, it clearly shows the com-
plexity of opioid systems and the
need to reconcile a range of findings.
How DORs might influence mor-
phine tolerance has been debated. Is
the effect mediated through indepen-
dent, but interacting, neuronal circuits
or by a direct molecular interaction
between the receptors? The possi-
bility of a direct interaction arose
with the demonstration of heterodi-
merization of MORs and DORs and
the demonstration that chronic
morphine administration upregulates
these heterodimers (Gupta et al.,
2010). In the current issue, He and
colleagues (He et al., 2011) extend
these findings, building upon a strong
foundation of work on opioid receptor
dimerization and trafficking (Gupta
et al., 2010; van Rijn et al., 2010; Von
Zastrow, 2010).
A role of m/d heterodimers in modu-
lating morphine actions requires their
coexpression in a single cell, a con-
cept that is controversial. It had long
been accepted that MORs and
DORs are coexpressed in small
dorsal root ganglion (DRG) neurons,
but recent work documenting the
limited selectivity of many of the
earlier antisera used to map DORs
and the inability to observe a fluores-
cent-tagged DOR in the small dorsal
root ganglia neurons containing
MOR-1 raised important questionsabout this concept. With these results,
the question was recently revisited and
evidence presented to support their coex-
pression in these neurons (Wang et al.,
2010). This work is further buttressed by
additional studies in the current paper.
However, we are still left with the question
of why the GFP-tagged DOR-1 was not
visualized in these neurons.
He et al. (2011) further propose that
activation of DORs within the m/d
heterodimer leads to the degradation of
the MORs and a diminished response, as
opposed to the recycling normally seen
(Von Zastrow, 2010). In the paper, they
presented strong evidence for the exis-
tence of the heterodimers and the traf-
ficking, both in cell lines and in tissue.
However, they lookedonlyatMOR-1 itself.
The MOR-1 gene undergoes extensive
alternative splicing, with over two dozen
splice variants identified in mice (Pan andPasternak, 2011). It is not yet clearwhether
all these variants form heterodimers with
DORs and, if so, whether their trafficking
mimics that of MOR-1. Indeed, evidence
has been presented that alternative splic-
ing of the C terminus of MOR-1 canmark-
edly impact trafficking patterns (Tanowitz
et al., 2008). Clearly, these issues need
further investigation in the future.
The major novelty of the paper comes
from their work with MORTM1-TAT, which
corresponds to the first transmembrane
domain of MOR-1. Their ability to use
the TAT domain to insert the peptide into
the membrane in the correct orientation
where it can interrupt the dimerization
process is particularly innovative. Here,
they observe that systemic administration
of the MORTM1-TAT led to its presence
within the neurons of the DRG and dorsal
horn of the spinal cord. This is quite
surprising in view of the general difficultiesNeuron 69,peptides have traversing the blood-
brain barrier. Its presence in the spinal
cord, however, raises the question of
whether it also is present within the
brain and whether it may be active
there as well.
Administration of MORTM1-TAT dis-
rupts the m/d heterodimers (Figure 1)
but not MOR-1 heterodimers contain-
ing a2A or NK-1 receptors. This implies
a specific site of interaction between
theDORs andMORs involving the first
transmembrane domain (TM1) of
MOR-1 but not others. When adminis-
tered systemically to naive animals,
MORTM1-TAT increased the response
of morphine given systemically and
blocked the development of toler-
ance. The results are quite dramatic
and consistent with their hypothesis.
However, a number of questions
remain. First is the question of the
site of action of MORTM1-TAT protein.
While the authors provide evidence for
activity at the spinal level, it is equally
possible that the responses might
involve supraspinal heterodimers.
Indeed, supraspinal sites are more
sensitive to systemic morphine than
spinal ones, as shown by the de-
creased potency of morphine
following spinal transaction in the tail-
flick assay. A more basic question is
whether MORTM1-TAT might alter
other types of associations as well.
The authors examined a2 and NK-1receptors, but MOR-1 will dimerize with
additional receptors, such as ORL1 and
even the other MOR-1 splice variants.
The activity of the single TM MORTM1-
TAT also raises a very interesting ques-
tion. Four human and five mouse alterna-
tively spliced MOR-1 variants generate
truncated proteins corresponding to the
first transmembrane domain of MOR-1
(Du et al., 1997; Pan and Pasternak,
2011), a structure very similar to
MORTM1-TAT. At least one of the single
TM variants has mRNA levels similar to
those of MOR-1 itself, implying a relatively
high level of expression. Are the actions of
the engineered MORTM1-TAT providing
insights into the actions of the endoge-
nous single TM variants? While the
evidence is strong that MORTM1-TAT can
disrupt the m/d heterodimer, might it also
have activity by blocking or mimicking
the naturally occurring TM1 variants?January 13, 2011 ª2011 Elsevier Inc. 7
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PreviewsThe current article by He et al. (2011)
presents an intriguing hypothesis on the
modulation of morphine analgesia by
heterodimerization of DORs with MORs.
It pulls together and confirms prior obser-
vations and extends them to provide an
explanation for how DORs modulate
morphine actions. It represents a signifi-
cant step forward in our understanding
of the basic mechanisms underlying
various aspects of opioid tolerance. Like
most goodscience, it also raises a number
of issues that need to be addressed in the
future. Some of these involve MOR-1
splice variants, both the full length ones
that can potentially dimerize with DORs
and the truncated single TM ones that
may have actions similar to those seen
with MORTM1-TAT. However, it is impor-
tant to remember that tolerance is like
a tug of war, with heterodimerization8 Neuron 69, January 13, 2011 ª2011 Elsevierepresenting only a single person pulling
on the rope.REFERENCES
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